JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB280042

Human PARK2 (Parkin) knockout SH-SY5Y cell line

Be the first to review this product! 리뷰 제출

|

(0 출판물)

PRKN KO cell line available to order. KO validated by Western blot. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 77 bp deletion in exon 2. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
2 이미지
Western blot - Human PARK2 (Parkin) knockout SH-SY5Y cell line (AB280042)
  • WB

Lab

Western blot - Human PARK2 (Parkin) knockout SH-SY5Y cell line (AB280042)

Lanes 1 - 4 : Merged signal (red and green). Green - ab77924 observed at 49 kDa. Red - loading control ab181602 (Rabbit Anti-GAPDH antibody [EPR16891]) observed at 37 kDa.

ab77924 was shown to react with Parkin in wild-type SH-SY5Y cells in Western blot with loss of signal observed in PRKN knockout cell line ab280042 (PRKN knockout cell lysate ab280101). Wild-type SH-SY5Y and PRKN knockout cell lysates were subjected to SDS-PAGE. Membranes were blocked in 3 % milk in TBS-T (0.1 % Tween®) before incubation with ab77924 and ab181602 (Rabbit Anti-GAPDH antibody [EPR16891]) overnight at 4 °C at 5 µg/ml and a 1 in 20000 dilution respectively. Blots were incubated with Goat anti-Mouse IgG H&L (IRDye® 800CW) preabsorbed (ab216772) and Goat anti-Rabbit IgG H&L (IRDye® 680RD) preabsorbed (ab216777) secondary antibodies at 1 in 20000 dilution for 1 h at room temperature before imaging.

All lanes:

Western blot - Anti-Parkin antibody [PRK8] (<a href='/ko/products/primary-antibodies/parkin-antibody-prk8-ab77924'>ab77924</a>) at 5 µg/mL

Lane 1:

Wild-type SH-SY5Y cell lysate at 20 µg

Lane 2:

PRKN knockout SH-SY5Y cell lysate at 20 µg

Lane 2:

Western blot - Human PARK2 (Parkin) knockout SH-SY5Y cell line (ab280042)

Lane 3:

Human Brain tissue lysate at 20 µg

Lane 4:

HUVEC cell lysate at 20 µg

Predicted band size: 52 kDa

Observed band size: 49 kDa

false

Sanger Sequencing - Human PARK2 (Parkin) knockout SH-SY5Y cell line (AB280042)
  • Sanger seq

Supplier Data

Sanger Sequencing - Human PARK2 (Parkin) knockout SH-SY5Y cell line (AB280042)

Human PRKN KO in SH-SY5Y Cells with 77 bp Deletion in Exon 2

주요 정보

세포 유형

SH-SY5Y

Species or organism

Human

조직

Bone marrow

제형

Liquid

form

Knockout 검증

Sanger Sequencing,Western blot

Mutation 정보

Knockout achieved by using CRISPR/Cas9, Homozygous: 77 bp deletion in exon 2

질병

Neuroblastoma

Reactivity 정보

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

제품 세부 정보

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

제품 구성

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab280042-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab280042 Human PARK2 (Parkin) knockout SH-SY5Y cell line", "number":"AB280042-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab275475 Human wild-type SH-SY5Y cell line", "number":"AB280042-CMP02" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab280042-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab280042 Human PARK2 (Parkin) knockout SH-SY5Y cell line", "number":"AB280042-CMP01", "productcode":"" } ] } } }

특성 및 보관 정보

유전자명
PRKN
유전자 편집 종류
Knockout
유전자 편집 방식
CRISPR technology
Knockout 검증
Sanger Sequencing, Western blot
Zygosity
Homozygous
품질 관리 - STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
배송 시 보관 조건
Dry Ice
적절한 단기 보관 조건
-196°C
적절한 장기 보관 조건
-196°C

추가 정보

This supplementary information is collated from multiple sources and compiled automatically.

The Parkin protein also known as PRK8 or Park2 is an E3 ubiquitin ligase with a molecular weight of approximately 52 kDa. This protein plays a critical role in tagging damaged proteins for degradation maintaining cellular health. Parkin is expressed in various tissues with significant levels in dopaminergic neurons in the brain. It is encoded by the PARK2 gene and has been linked to the regulation of mitochondrial quality and autophagy processes contributing to cellular homeostasis.
Biological function summary

Parkin is essential for the regulation of mitochondria through its involvement in the mitochondrial quality control system. It functions as part of a complex with other proteins that respond to mitochondrial damage by tagging them with ubiquitin molecules. This mechanism allows for the removal of defective mitochondria via mitophagy critical for preventing the accumulation of damaged cellular components.

Pathways

Parkin interacts with pathways involved in the cellular stress response particularly the PINK1 (PTEN Induced Kinase

  1. pathway. PINK1 phosphorylates Parkin activating it to label damaged mitochondria. Another critical pathway involves proteasomal degradation where Parkin collaborates with Ubiquitin to manage protein turnover. These pathways highlight its relationships with other cellular stress-regulating proteins enhancing our understanding of its roles in maintaining cellular integrity.
Mutations in the gene coding for Parkin are linked to Parkinson's disease (PD) and some forms of juvenile autosomal recessive parkinsonism. The Parkin protein's dysfunctional activity leads to impaired mitochondrial management and protein aggregation in neurons contributing significantly to neurodegenerative disease. In conditions such as PD Parkin interacts with other proteins such as PINK1 reinforcing its role in mitochondrial protection and indicating the protein's importance in disease progression and potential therapeutic targeting.

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Female

초기 취급 지침

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability. <p>1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.<br>2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.<br>3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.<br>4. Incubate the culture at 37°C incubator with 5% CO<sub>2</sub>. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.<br>5. Once confluent passage into an appropriate flask at a density of 2x10<sup>4</sup> cells/cm<sup>2</sup>. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.</p>

Subculture 가이드라인
  • All seeding densities should be based on cell counts gained by established methods.
  • These cells grow as a mixture of floating and adherent cells.
  • Remove media containing floating cells and recover cells by centrifugation, detach cells using standard methods, combine with floating cells and transfer to a new culture flask.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be seeded at a density conducive to cell–cell communication to proliferate. If cells are seeded too sparsely, growth rate is reduced and cell death is high.
배양 배지

1:1 mixture of EMEM and F-12K + 10% FBS

동결보존 배지

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

제품 프로토콜

타겟 정보

See full target information PRKN

대체 명칭 보기

Parkin RBR E3 ubiquitin-protein ligase, PRKN, E3 ubiquitin-protein ligase parkin, PARK2, Parkinson juvenile disease protein 2, Parkinson disease protein 2, Parkin

Product promise

저희는 고품질 시약으로 고객님의 연구를 서포트하고자 최선을 다하고 있으며, 모든 단계에서 함께 하겠습니다. 만약 제품이 기대한 성능을 보이지 않을 경우에도 Product Promise로 보호받으실 수 있습니다.
자세한 내용은 이용 약관을 확인해 주세요.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com